免疫治疗在恶性胸膜间皮瘤中的应用

Application of immunotherapy in malignant pleural mesothelioma

近年来,免疫检查点抑制剂已经改变了多种恶性肿瘤的治疗,目前针对特异性靶点的免疫治疗在黑色素瘤、肺癌等多个肿瘤中都发挥着重要作用。恶性胸膜间皮瘤(malignant pleural mesothelioma,MPM)是一种具有侵袭性的恶性肿瘤,目前治疗手段虽涵盖手术、化疗以及放疗等,但临床疗效有限,进展期患者预后不佳。随着程序性死亡受体1/程序性死亡-配体1及细胞毒性T淋巴细胞相关蛋白4等单克隆抗体的应用,MPM患者有了更多的治疗选择。相对于传统化疗手段,免疫治疗可能有缩小肿瘤以及提高生存效益的效果。本文将总结目前在MPM中免疫治疗的临床试验,从单药免疫治疗及联合免疫治疗两方面来阐述目前免疫治疗在MPM的应用及进展。

In recent years,immune checkpoint inhibitor therapy has changed the treatment of various malignant tumors.Immunotherapy for specific targets currently plays an important role in melanoma,lung cancer and other tumors.Malignant pleural mesothelioma(MPM)is an aggressive malignant tumor.Although the treatments include surgery,chemotherapy and radiotherapy,the clinical efficacy is limited,and the prognosis of advanced patients is poor.With the application of monoclonal antibodies such as programmed death 1/programmed death ligand 1 and cytotoxic Tlymphocyte antigen 4,MPM patients have more treatment options.And compared with traditional chemotherapy,immunotherapy may have the effect of improving survival and shrinking tumors.This article will summarize the current clinical trials of immunotherapy in MPM,and explain the current application and progress of immunotherapy in MPM from both single-agent immunotherapy and combined immunotherapy.